Nonpartisan civic infrastructure
AllCiv·Legis1
·

S. 3143

BillFederalSenateIn Committee
To establish postmarket reporting requirements for pharmaceuticals, and for other purposes.
About This Bill
Committee
Latest Action · October 26, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Congress
118th (2023–2025)
Introduced
October 26, 2023
Cosponsors (2)
0D 2R
View PDF ↗

Summary

Highlight any text to annotate
This bill requires pharmaceutical companies to provide detailed supply chain information to the federal government and strengthens oversight of drug manufacturing. Specifically, drug manufacturers must report annually to the Food and Drug Administration about where they source all active and inactive ingredients and what percentage comes from each supplier. The FDA will share this information with the Department of Defense to assess U.S. military medicine supply vulnerabilities and publish aggregated data publicly on a government website without revealing proprietary details. The bill also updates federal contracting rules to ensure active pharmaceutical ingredients used by the government meet U.S. origin standards and gives FDA inspectors authority to examine whether drug and device manufacturers are located in countries with histories of exporting illicit drugs or are inspected by foreign adversaries. These changes take effect within 180 days of enactment and aim to reduce American dependence on foreign pharmaceutical suppliers and strengthen national security.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.